Payment overview · 2025
General Payments
$1,700.45
84 reported records · 28 companies
Healthcare provider profile · identity verified
William S Dacus, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, SC · NPI 1336162403
Verified facts
What the public records show
CMS Open Payments records show William S Dacus, MD received $1,700.45 in general payments during 2025 across 84 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Gemtesa, Jardiance, Mounjaro, Nurtec Odt, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $247.19 | 14.5% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $190.11 | 11.2% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $134.81 | 7.9% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $127.40 | 7.5% | 6 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $118.37 | 7.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.33 | 5.2% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $86.83 | 5.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.36 | 4.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.03 | 3.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.74 | 3.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.65 | 3.1% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.56 | 2.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $45.25 | 2.7% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $42.84 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.43 | 2.5% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $33.87 | 2.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.95 | 1.9% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $31.38 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.41 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.30 | 1.4% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $23.45 | 1.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.43 | 1.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.14 | 1.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.02 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.18 | 0.9% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.46 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.28 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.68 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,700.45 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $153.40 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $138.38 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $134.81 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $134.81 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $119.78 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $116.93 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $116.93 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.18 | 4 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $62.99 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $62.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.03 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $56.74 | 4 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $55.38 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.65 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.30 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $47.56 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.25 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $42.84 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.70 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.91 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $33.87 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $31.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 46 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 122 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
122 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 383 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 367 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 363 | 108 |
| Lisinopril | Lisinopril | 326 | 87 |
| Gabapentin | Gabapentin | 269 | 87 |
| Metformin Hcl | Metformin Hcl | 253 | 69 |
| Omeprazole | Omeprazole | 250 | 72 |
| Alprazolam | Alprazolam | 241 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 221 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 61 |
| Clonazepam | Clonazepam | 199 | 26 |
| Furosemide | Furosemide | 188 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 188 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 186 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 53 |
| Trazodone Hcl | Trazodone Hcl | 169 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 63 |
| Lorazepam | Lorazepam | 160 | 27 |
| Montelukast Sodium | Montelukast Sodium | 151 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 40 |
| Meloxicam | Meloxicam | 139 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 139 | 40 |
| Sertraline Hcl | Sertraline Hcl | 129 | 36 |
| Tramadol Hcl | Tramadol Hcl | 126 | 27 |
| Carvedilol | Carvedilol | 125 | 34 |
| Chlorthalidone | Chlorthalidone | 122 | 36 |
| Farxiga | Dapagliflozin Propanediol | 122 | 25 |
| Jardiance | Empagliflozin | 122 | 31 |
| Losartan Potassium | Losartan Potassium | 121 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 31 |
| Telmisartan | Telmisartan | 117 | 33 |
| Celecoxib | Celecoxib | 109 | 39 |
| Eliquis | Apixaban | 104 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 93 | 23 |
| Pregabalin | Pregabalin | 92 | 23 |
| Simvastatin | Simvastatin | 88 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 19 |
| Allopurinol | Allopurinol | 82 | 28 |
| Bupropion Xl | Bupropion Hcl | 77 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 15 |
| Ezetimibe | Ezetimibe | 73 | 21 |
| Ozempic | Semaglutide | 73 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 70 | 18 |
| Diazepam | Diazepam | 70 | 13 |
| Buspirone Hcl | Buspirone Hcl | 69 | 21 |
| Potassium Chloride | Potassium Chloride | 69 | 23 |
| Colesevelam Hcl | Colesevelam Hcl | 68 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 16 |
| Prednisone | Prednisone | 64 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 15 |
| Synthroid | Levothyroxine Sodium | 59 | 12 |
| Torsemide | Torsemide | 59 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 24 |
| Ramipril | Ramipril | 58 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 13 |
| Spironolactone | Spironolactone | 55 | 19 |
| Glimepiride | Glimepiride | 54 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 15 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 16 |
| Mirtazapine | Mirtazapine | 51 | 20 |
| Donepezil Hcl | Donepezil Hcl | 50 | 14 |
| Meclizine Hcl | Meclizine Hcl | 50 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 49 | 29 |
| Eszopiclone | Eszopiclone | 48 | suppressed |
| Irbesartan | Irbesartan | 48 | 12 |
| Ondansetron Odt | Ondansetron | 47 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 17 |
| Entresto | Sacubitril/Valsartan | 46 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 12 |
| Ketoconazole | Ketoconazole | 45 | 23 |
| Metformin Hcl Er | Metformin Hcl | 45 | 13 |
| Promethazine Hcl | Promethazine Hcl | 45 | 15 |
| Doxepin Hcl | Doxepin Hcl | 44 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 13 |
| Valsartan | Valsartan | 43 | 13 |
| Januvia | Sitagliptin Phosphate | 42 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Famotidine | Famotidine | 41 | 20 |
| Methocarbamol | Methocarbamol | 40 | 13 |
| Diclofenac Potassium | Diclofenac Potassium | 39 | 19 |
| Rybelsus | Semaglutide | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 28 |
| Baclofen | Baclofen | 36 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 25 |
| Mupirocin | Mupirocin | 32 | 22 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 32 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Atenolol | Atenolol | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Repaglinide | Repaglinide | 28 | suppressed |
| Colchicine | Colchicine | 27 | 13 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 11 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Fluconazole | Fluconazole | 18 | 13 |
| Glipizide | Glipizide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Zaleplon | Zaleplon | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,700.45 · 84 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AMS 700, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, CLOTTRIEVER BOLD CATHETER, CONTRAVE, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, ENTRESTO, EVENITY, FARXIGA, FLOWTRIEVER CATHETER, S, GARDASIL 9, GEMTESA, Heplisav-B, INJECTAFER, JARDIANCE, KRYSTEXXA, Korlym, MOUNJARO, NEXLETOL, NUPLAZID, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, REPATHA, REXULTI, SHINGRIX, Symbravo, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error